

## A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- diagnosis of ER+, HER2- early-stage invasive breast cancer without evidence of distant metastasis - completed surgery - received at least 24 months but not more than 60 months of any endocrine therapy after treatment - may be limited with strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work

---

#### Exclusion Criteria:

- any evidence of metastatic disease - more than a 6 month consecutive gap in therapy during the course of prior adjuvant endocrine therapy - history of any other cancer - women who are pregnant, breastfeeding, or expecting to conceive or men expecting to father children

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Breast cancer, ER+, Hormone positive, hormone therapy

### More Information

**Description:** Disruption of estrogen signaling by drugs called selective estrogen receptor degraders (SERDs) is one of the treatment options for patients with estrogen receptor positive (ER+) cancers. Imlunestrant is a SERD that disrupts estrogen signaling, and therefore should stop or slow down tumor growth in ER+ cancers. This study will help answer research questions about the safety of imlunestrant and any side effects, and how imlunestrant compares to standard-of-care endocrine therapy.

**Study Contact:** Kris DeBoer - [kdeboer1@fairview.org](mailto:kdeboer1@fairview.org)

**Principal Investigator:** Kiran Lassi

#### IRB

**Number:** STUDY00018436

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.